We aim to test the hypothesis that high plasma YKL-@ is associated with short progression-free survival ( PFS ) and overall survival ( OS ) in patients with metastatic colorectal cancer ( mCRC ) treated with first-line oxaliplatin and @-flourouracil with or without cetuximab .